News

The financing was co-led by Quaker BioVentures and MedImmune Ventures. Other investors included Red Abbey Venture Partners, Maryland Health Care Product Development Corporation and Acidophil. The company said

As part of the agreement GlaxoSmithKline Biologicals (GSK) is acquiring exclusive rights to develop and commercialize two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology

IT-101 is an experimental, nanoparticle therapeutic that consists of the drug camptothecin conjugated to a cyclodextrin polymer. IT-101, the first drug candidate in Calando’s proprietary Cyclosert pipeline, has

The latest analysis focused on a prospective group of patients (n=50) with an annualized relapse rate (ARR) of greater than one at study entry which is comparable to

This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. This data provide the scientific rationale for an ongoing

Most recently, Mr Arlotta has served as chairman, president and CEO of Coram, a provider of specialty infusion and pharmacy distribution services that was acquired by Apria Healthcare

Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature, said Schering-Plough. The study was a randomized, placebo-controlled, double-blind,

Synexus hopes to have the new sites completed by March 2009. Synexus, which acquired the clinical trial business CRC in 2006, said that it has found South Africa

Celera will use Nanogen’s minor groove binder (MGB) technology to develop in vitro diagnostic products for cardiovascular and oncological applications. This is an expansion of the original license